Expression of FR-β and CD34 in AML patient bone marrow aspirates determined by flow cytometry
| FAB class (total) . | FR-β+ . | FR-β+/CD34+ . |
|---|---|---|
| M0 (1) | 0 | 0 |
| M1 (9) | 3 | 2 |
| M2 (10) | 4 | 4 |
| M3 (4) | 3 | 0 |
| M4 (13) | 11 | 9 |
| M5 (11) | 11 | 6 |
| M6 (2) | 2 | ND |
| ND (28) | 19 | 14 |
| FAB class (total) . | FR-β+ . | FR-β+/CD34+ . |
|---|---|---|
| M0 (1) | 0 | 0 |
| M1 (9) | 3 | 2 |
| M2 (10) | 4 | 4 |
| M3 (4) | 3 | 0 |
| M4 (13) | 11 | 9 |
| M5 (11) | 11 | 6 |
| M6 (2) | 2 | ND |
| ND (28) | 19 | 14 |
Total number of AML samples tested: 78.
Number of samples in which 100% of the cells were FR-β+: 38.
Number of samples in which 80%-90% of cells were FR-β+: 4.
Number of samples in which 30%-60% of cells were FR-β+: 8.
Total number of FR-β+ AML samples: 53.
Percentage FR-β+ samples: 68.
Percentage positivity represents the fraction of cells in each sample that gave a positive peak-shift with anti–FR-β antibody relative to the threshold for each sample defined by the peak position of the antibody isotype control.
ND indicates not determined.